Journal
CLINICAL PHARMACOKINETICS
Volume 57, Issue 5, Pages 637-644Publisher
ADIS INT LTD
DOI: 10.1007/s40262-017-0582-9
Keywords
-
Categories
Funding
- Novartis
Ask authors/readers for more resources
Background The mammalian target of rapamycin (mTOR) inhibitor everolimus is used in the treatment of breast cancer, neuroendocrine tumors, and renal cancer. The approved 10 mg once-daily dose is associated with considerable adverse effects and it has been suggested that these are associated with the maximum concentration (C-max) of everolimus. Twice-daily dosing might be an alternative strategy with improved tolerability; however, a direct pharmacokinetic comparison of 10 mg once-daily with 5 mg twice-daily dosing is lacking. Methods We performed a prospective, randomized, pharmacokinetic, crossover trial comparing everolimus 10 mg once daily with 5 mg twice daily. Patients received the first dose schedule for 2 weeks and then switched to the alternative regimen for 2 weeks. Pharmacokinetic sampling was performed on days 14 and 28. Results Eleven patients were included in the study, of whom 10 were evaluable for pharmacokinetic analysis. On the 10 mg once-daily schedule, C-max, minimum concentration (C-min), and area under the concentration-time curve from time zero to 24 h (AUC(24)) were 61.5 ng/mL [mean percentage coefficient of variation (CV%) 29.6], 9.6 ng/mL (CV% 35.0), and 435 ng h/mL (CV% 28.1), respectively. Switching to the 5 mg twice-daily schedule resulted in a reduction of C-max to 40.3 ng/mL (CV% 46.6) (p = 0.013), while maintaining AUC(24) at 436 ng h/mL (CV% 34.8) (p = 0.952). C-min increased to 13.7 ng/mL (CV% 53.9) (p = 0.018). The overall reduction in C-max was 21.2 ng/mL, or 32.7%. The C-max/C-min ratio was reduced from 6.44 (CV% 36.2) to 3.18 (CV% 35.5) (p < 0.001). Conclusions We demonstrated that switching from a once-daily to a twice-daily everolimus dose schedule reduces C-max without negatively impacting C-min or AUC(24). These results merit further investigation of the twice-daily schedule in an effort to reduce everolimus toxicity while maintaining treatment efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available